MSI-H/dMMR亚组局部晚期结直肠癌患者新辅助免疫治疗研究进展

doi:10.3760/cma.j.cn441417-20240924-08009

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (8): 1270-1274.DOI: 10.3760/cma.j.cn441417-20240924-08009

MSI-H/dMMR亚组局部晚期结直肠癌患者新辅助免疫治疗研究进展

刘汉清¹ 孙银萍² 赵强² 任帅²

¹滨州医学院，滨州 256600；²淄博市中心医院，淄博 250036

收稿日期:2024-09-24 出版日期:2025-04-15 发布日期:2025-04-20
通讯作者: 赵强，Email：qiangzhao1973@163.com
基金资助:
国家中医药管理局科技司-山东省卫生健康委员会共建中医药科技项目（GZY-KJS-SD-2023-010）；山东省中医药科技项目（Z-2022013）；北京科创医学发展基金会科技项目（KC2023-JX-0288-PM91）；山东省自然科学基金青年项目（ZR2022QH392）；淄博市卫生健康青年卓越人才孵站培养基金（202210）

Research progress on neoadjuvant immunotherapy for MSI-H/dMMR subtype patients with locally advanced colorectal cancer

Liu Hanqing¹, Sun Yinping², Zhao Qiang², Ren Shuai²

¹Binzhou Medical University, Binzhou 256600, China; ²Zibo Central Hospital, Zibo 250036, China

Received:2024-09-24 Online:2025-04-15 Published:2025-04-20
Contact: Zhao Qiang, Email: qiangzhao1973@163.com
Supported by:
Science and Technology Project of Traditional Chinese Medicine Jointly Built by Department of Science and Technology, State Administration of Traditional Chinese Medicine and Shandong Provincial Health Commission (GZY-KJS-SD-2023-010); Science and Technology Project of Traditional Chinese Medicine in Shandong (Z-2022013); Science and Technology Project of Beijing Science and Technology Innovation Medical Development Foundation (KC2023-JX-0288-PM91); Youth Project of Shandong Provincial Natural Science Foundation (ZR2022QH392); Zibo City Health Youth Excellent Talent Incubation Station Training Fund (202210)

摘要/Abstract

摘要：

近年来，全程新辅助治疗广泛应用于局部晚期结直肠癌（locally advanced colorectal cancer，LACRC）患者的治疗，显著提高了患者术前肿瘤消退率，降低了术后局部区域复发风险。新辅助免疫治疗在LACRC患者中的应用取得了良好的临床效果。新辅助免疫治疗单用或联合新辅助放化疗续贯手术治疗成为了LACRC患者新的治疗方式。根据错配修复蛋白表达，结直肠癌（colorectal cancer，CRC）可分为微卫星高度不稳定/错配修复功能缺陷（microsatellite hyperinstability/mismatch repair functional defects，MSI-H/dMMR）和非微卫星高度不稳定/错配修复功能完整（non-microsatellite high instability/mismatch repair is complete，非MSI-H/pMMR）2个亚组。MSI-H/dMMR亚组患者从放化疗中取得的临床获益有限，但由于其肿瘤组织中免疫细胞浸润丰富，可以从免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）治疗中获得良好的效果。本文对新辅助免疫治疗在MSI-H/dMMR亚组LACRC患者中的临床应用进行综述，讨论其治疗LACRC患者的优势，为LACRC患者术前新辅助治疗提供参考。

关键词:

局部晚期结直肠癌, 新辅助免疫治疗, 错配修复功能缺陷, 微卫星高度不稳定, 进展

Abstract:

In recent years, neoadjuvant therapy is widely used in the treatment of locally advanced colorectal cancer (LACRC), and has significantly improved the preoperative tumor regression rate and reduced the risk of postoperative local recurrence. Neoadjuvant immunotherapy has achieved favorable clinical effects in the treatment of LACRC. Neoadjuvant immunotherapy with or without neoadjuvant chemoradiotherapy followed by surgery had become a new therapeutic method for LACRC. Based on the expression of mismatch repair proteins, colorectal cancer (CRC) can be divided into two subgroups: microsatellite highly unstable/mismatch repair dysfunction (MSI-H/dMMR) and non-microsatellite highly unstable/ mismatch repair function complete (non-MSI-H/pMMR). MSI-H/dMMR patients obtain limited clinical benefits from chemoradiotherapy, but have favorable clinical effects in immune checkpoint inhibitors (ICIs) treatment due to the abundant immune cell infiltration. This article reviews and discusses the clinical application and advantages of neoadjuvant immunotherapy in MSI-H/dMMR LACRC patients, so as to provide references for the preoperative neoadjuvant treatment for LACRC.

Key words:

Locally advanced colorectal cancer, Neoadjuvant immunotherapy, Mismatch repair function defects, Microsatellite highly unstable, Progress

刘汉清孙银萍赵强任帅.

MSI-H/dMMR亚组局部晚期结直肠癌患者新辅助免疫治疗研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1270-1274.

Liu Hanqing, Sun Yinping, Zhao Qiang, Ren Shuai.

Research progress on neoadjuvant immunotherapy for MSI-H/dMMR subtype patients with locally advanced colorectal cancer [J]. International Medicine and Health Guidance News, 2025, 31(8): 1270-1274.

参考文献

[1] Weng J, Li S, Zhu Z, et al. Exploring immunotherapy in colorectal cancer [J]. J Hematol Oncol, 2022, 15(1): 95. DOI: 10.1186/s13045-022-01294-4.
[2] Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective [J]. Int J Biol Sci, 2021, 17(14): 3837-3849. DOI: 10.7150/ijbs.64077.
[3] Zhang X, Wu T, Cai X, et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities [J]. Front Immunol, 2022, 13: 795972. DOI: 10.3389/fimmu.2022.795972.
[4] Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy [J]. Cancer Treat Rev, 2019, 76: 22-32. DOI: 10.1016/j.ctrv.2019.04.003.
[5] Pei L, Liu Y, Liu L, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers [J]. Mol Cancer, 2023, 22(1): 29. DOI: 10.1186/s12943-023-01731-z.
[6] Bai Z, Zhou Y, Ye Z, et al. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy [J]. Front Immunol, 2022, 12: 808964. DOI: 10.3389/fimmu.2021.808964.
[7] Ding K, Mou P, Wang Z, et al. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer [J]. Front Immunol, 2023, 14: 1298524. DOI: 10.3389/fimmu.2023.1298524.
[8] De' Angelis GL, Bottarelli L, Azzoni C, et al. Microsatellite instability in colorectal cancer [J]. Acta Biomed, 2018, 89(9-S): 97-101. DOI: 10.23750/abm.v89i9-S.7960.
[9] Chen G, Jin Y, Guan WL, et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study [J]. Lancet Gastroenterol Hepatol, 2023, 8(5): 422-431. DOI: 10.1016/S2468-1253(22)00439-3.
[10] Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon [J]. Science, 1993, 260(5109): 816-819. DOI: 10.1126/science.8484122.
[11] Qiu B, Ding PR, Cai L, et al. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer [J]. Chin J Cancer, 2016, 35(1): 65. DOI: 10.1186/s40880-016-0126-y.
[12] Ratti F, Catena M, Di Palo S, et al. Impact of totally laparoscopic combined management of colorectal cancer with synchronous hepatic metastases on severity of complications: a propensity-score-based analysis [J]. Surg Endosc, 2016, 30(11): 4934-4945. DOI: 10.1007/s00464-016-4835-8.
[13] Lichtenstern CR, Ngu RK, Shalapour S, et al. Immunotherapy, inflammation and colorectal cancer [J]. Cells, 2020, 9(3): 618. DOI: 10.3390/cells9030618.
[14] Seo I, Lee HW, Byun SJ, et al. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer [J]. J Immunother Cancer, 2021, 9(3): e001610. DOI: 10.1136/jitc-2020-001610.
[15] Wu Y, Zhuang J, Qu Z, et al. Advances in immunotyping of colorectal cancer [J]. Front Immunol, 2023, 14: 1259461. DOI: 10.3389/fimmu.2023.1259461.
[16] Yaghoubi N, Soltani A, Ghazvini K, et al. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer [J]. Biomed Pharmacother, 2019, 110: 312-318. DOI: 10.1016/j.biopha.2018.11.105.
[17] Chen JT, Zhou YW, Han TR, et al. Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions [J]. Front Immunol, 2023, 14:1269341. DOI: 10.3389/fimmu.2023.1269341.
[18] Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer [J]. N Engl J Med, 2022, 386(25): 2363-2376. DOI: 10.1056/NEJMoa2201445.
[19] Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J]. Lancet Oncol, 2017, 18(9): 1182-1191. DOI: 10.1016/S1470-2045(17)30422-9.
[20] Kanani A, Veen T, Søreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer [J]. Br J Surg, 2021, 108(12): 1417-1425. DOI: 10.1093/bjs/znab342.
[21] André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med, 2020, 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699.
[22] André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med, 2020, 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699.
[23] Qin Q, Yang K, Ma T, et al. Serial circulating tumor DNA in monitoring the effect of neoadjuvant and adjuvant immunotherapy in patients with colon cancer: case series and review of the literature [J]. J Immunother, 2022, 45(8): 358-362. DOI: 10.1097/CJI.0000000000000436.
[24] Han K, Tang JH, Liao LE, et al. Neoadjuvant immune checkpoint inhibition improves organ preservation in T4bM0 colorectal cancer with mismatch repair deficiency: a retrospective observational study [J]. Dis Colon Rectum, 2023, 66(10): e996-e1005. DOI: 10.1097/DCR.0000000000002466.
[25] Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J]. Nat Med, 2020, 26(4): 566-576. DOI: 10.1038/s41591-020-0805-8.
[26] Chen M, Chen J, Huang J, et al. Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy [J]. Therap Adv Gastroenterol, 2023, 16:1 7562848221150306. DOI: 10.1177/17562848221150306.
[27] Lau D, Kalaitzaki E, Church DN, wt al. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage Ⅲ mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase Ⅲ randomised study [J]. ESMO Open, 2020, 5(1): e000638. DOI: 10.1136/esmoopen-2019-000638.
[28] Zhou P, Wang Y, Qin S, et al. Abscopal effect triggered by radiation sequential mono-immunotherapy resulted in a complete remission of PMMR sigmoid colon cancer [J]. Front Immunol, 2023, 14: 1139527. DOI: 10.3389/fimmu.2023.1139527.
[29] Liu S, Zhang Y, Lin Y, et al. Case report: the MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy [J]. Front Immunol, 2022, 13: 981527. DOI: 10.3389/fimmu.2022.981527.
[30] Corrò C, Buchs NC, Tihy M, et al. Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer [J]. BMC Cancer, 2022, 22(1): 772. DOI: 10.1186/s12885-022-09820-w.
[31] Li X, Fang C, Wang X, et al. Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI-H/dMMR rectal cancer: A prospective, multicenter, phase Ib study [J]. Cancer Med, 2022, 11(23): 4405-4410. DOI: 10.1002/cam4.4720.
[32] Zhai ML, Zhang FY, Yang JR, et al. Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer Center [J]. Radiat Oncol, 2022, 17(1): 109. DOI: 10.1186/s13014-022-02081-8.
[33] Lin Z, Cai M, Zhang P, et al. Phase Ⅱ, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer [J]. J Immunother Cancer, 2021, 9(11): e003554. DOI: 10.1136/jitc-2021-003554.
[34] Gao J, Zhang X, Yang Z, et al. Interim result of phase Ⅱ, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer [J]. Front Oncol, 2023, 13: 1057947. DOI: 10.3389/fonc.2023.1057947.
[35] Wang Y, Shen L, Wan J, et al. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase Ⅱ trial (TORCH) [J]. BMC Cancer, 2022, 22(1): 274. DOI: 10.1186/s12885-022-09348-z.
[36] Hanna CR, O'Cathail SM, Graham JS, et al. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) [J]. Radiat Oncol, 2021, 16(1): 163. DOI: 10.1186/s13014-021-01888-1.
[37] Keam SJ. Toripalimab: first global approval [J]. Drugs, 2019, 79(5): 573-578. DOI: 10.1007/s40265-019-01076-2.
[38] Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial [J]. Lancet Gastroenterol Hepatol, 2022, 7(1): 38-48. DOI: 10.1016/S2468-1253(21)00348-4.
[39] Verschoor YL, Van Den Berg J, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study [J]. J Clin Oncol, 2022, 40(16 Suppl): 3511-3511. DOI: 10.1200/JCO.2022.40.16_suppl.3511.
[40] Benson Z, Manjili SH, Habibi M, et al. Conditioning neoadjuvant therapies for improved immunotherapy of cancer [J]. Biochem Pharmacol, 2017, 145: 12-17. DOI: 10.1016/j.bcp.2017.08.007.
[41] Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J]. Nat Med, 2020, 26(4): 566-576. DOI: 10.1038/s41591-020-0805-8.
[42] VERSCHOOR Y L, VAN DEN BERG J, BEETS G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.[J/OL]. Journal of Clinical Oncology, 2022, 40(16_suppl): 3511-3511. DOI:10.1200/JCO.2022.40.16_suppl.3511.
[43] Zhang X, Yang R, Wu T, et al. Efficacy and safety of neoadjuvant monoimmunotherapy with PD-1 inhibitor for dMMR/MSI⁃H locally advanced colorectal cancer: a single-center real-world study [J]. Front Immunol, 2022, 13: 913483. DOI: 10.3389/fimmu.2022.913483.
[44] Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2021, 19(3): 329-359. DOI: 10.6004/jnccn.2021.0012.
[45] Liu S, Zhang Y, Lin Y, et al. Case report: the MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy [J]. Front Immunol, 2022, 13: 981527. DOI: 10.3389/fimmu.2022.981527.

MSI-H/dMMR亚组局部晚期结直肠癌患者新辅助免疫治疗研究进展

Research progress on neoadjuvant immunotherapy for MSI-H/dMMR subtype patients with locally advanced colorectal cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李强. 超声引导下射频消融治疗甲状腺微小乳头状癌的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1258-1260.
[2]	洪金全黄震宇黄惠炆黄豪博. 胸苷酸合成酶基因在肿瘤发生发展中的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1260-1265.
[3]	蒋萌赵静如刘惠刘庆新. 自噬与缺血性脑血管疾病的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1265-1269.
[4]	朱鹏唐文玲覃刚. 结直肠癌中微小RNA功能及临床价值进展 [J]. 国际医药卫生导报, 2025, 31(6): 886-890.
[5]	潘文昕姜伟炜. 结肠镜检查时机对缺血性结肠炎患者预后影响的研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 914-917.
[6]	张子怡孙大康. TRIM22抗HIV-1作用机制研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 918-922.
[7]	易伟米倩倩赵洁李博宇王丹. 彩色多普勒血流成像在球后血流动力学检测中的应用 [J]. 国际医药卫生导报, 2025, 31(6): 922-926.
[8]	陈秀珠张凯韦岩笑丛晨阳. 甲状腺相关眼病的药物治疗研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 927-929.
[9]	李晓童于胜强. 肾小管细胞来源外泌体在肾纤维化中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 712-718.
[10]	张涵孙婷王延飞张肖林车娟. 移植后淋巴组织增生性疾病在儿童扁桃体腺样体肥大中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 752-757.
[11]	莫家婵范万峰姜兴岳. 基于磁共振成像的影像组学在垂体腺瘤中的应用现状及进展 [J]. 国际医药卫生导报, 2025, 31(5): 757-760.
[12]	刘伟锋郭媛唐文洁杨蕊梦樊浩魏新华. “医+X”人才培养模式对医学影像研究生综合能力培养的初探 [J]. 国际医药卫生导报, 2025, 31(4): 530-534.
[13]	郝慧慧冯安华马晓林李敖丁传华. SOAP思维模式下融合案例与问题教学模式在临床药学实习带教中的应用 [J]. 国际医药卫生导报, 2025, 31(4): 539-542.
[14]	洪金全黄晓玲黄震宇黄豪博. 弥漫大B细胞淋巴瘤中脂质代谢异常及其干预的研究进展 [J]. 国际医药卫生导报, 2025, 31(4): 559-562.
[15]	王兴兴张肖林王延飞. 间充质干细胞在神经退行性疾病中的研究进展 [J]. 国际医药卫生导报, 2025, 31(4): 562-567.